Almirall SA
OTC:LBTSF
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.01
15.47
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| ES |
|
Almirall SA
MAD:ALM
|
2.8B EUR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
982.2B USD |
Loading...
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
526.1B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
277.8B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
217.9B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.7B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
213.9B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.8B USD |
Loading...
|
Market Distribution
| Min | -9 204.1% |
| 30th Percentile | 2.1% |
| Median | 10.5% |
| 70th Percentile | 19.8% |
| Max | 603.4% |
Other Profitability Ratios
Almirall SA
Glance View
Almirall SA, a venerable player in the pharmaceutical industry, has its roots deeply embedded in the Spanish landscape where it began its journey in 1943. With a commitment to innovation and a keen focus on dermatology, the company has carved out a significant niche for itself. Almirall's core strategy revolves around the development, manufacturing, and commercialization of its proprietary medications, particularly those targeting skin conditions such as psoriasis and atopic dermatitis. By investing heavily in research and development, Almirall ensures its pipeline remains robust with promising drug candidates and innovative therapies that can meet the unmet needs of dermatology patients. This focus gives them a strategic edge, allowing them to leverage their scientific expertise and deliver state-of-the-art solutions to the market. The financial health of Almirall thrives on a clear business model that involves both direct sales and strategic partnerships. Through collaborations with other pharmaceutical giants and dynamic distribution networks, the company expands its reach beyond Europe, tapping into the American and Asian markets as well. Licensing agreements and co-development partnerships are key to its financial strategy, effectively allowing Almirall to maximize its intellectual property while sharing risks and costs. This multi-pronged approach ensures a steady revenue stream from both its branded products and its generics division, which supplements the overall profitability and sustainability of the company. As Almirall continues to navigate the competitive landscape of the pharma industry, its resilience and adaptability underscore its enduring legacy.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Almirall SA is 3.5%, which is above its 3-year median of -0.3%.
Over the last 3 years, Almirall SA’s Net Margin has increased from 2.7% to 3.5%. During this period, it reached a low of -4.3% on Dec 31, 2023 and a high of 3.5% on Oct 30, 2025.